10x Genomics (TXG) Tops Q1 EPS by 16c, Revenues Beat; Offers FY21 Revenues Mid-Point Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. HUMA
3. NAVN
4. SPY
5. USO
6. cASY
7. CHWY
8. SNDX
9. HNGE
10. SPCX

Go back to 10x Genomics (TXG) Tops Q1 EPS by 16c, Revenues Beat; Offers FY21 Revenues Mid-Point Guidance Below Consensus

10x Genomics Reports First Quarter 2021 Financial Results

May 5, 2021 4:03 PM EDT

PLEASANTON, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2021.

Recent Highlights

Revenue was $105.8 million for the first quarter, representing a 47% increase over the corresponding period of 2020Launched Single Cell Gene Expression with CellPlex and Chromium Single Cell Gene Expression Low Throughput Kits to increase access to and affordability of single cell analysis and enable single cell... More